Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections

Bioengineered Bugs

Volumn 1, Issue 5, 2010, Pages 313-325

  Medina, Marcela ^a,b   Vintiñi, Elisa ^a   Villena, Julio ^a   Raya, Raul ^a   Alvarez, Susana ^a,b  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

Lactococcus lactis; Recombinant vaccine; Streptococcus pneumoniae

Indexed keywords

ADJUVANT; DRUG VEHICLE; INACTIVATED VACCINE; LIVE VACCINE; PNEUMOCOCCUS VACCINE; PROBIOTIC AGENT; RECOMBINANT VACCINE;

ANTIGEN EXPRESSION; DRUG DELIVERY SYSTEM; GENE EXPRESSION SYSTEM; IMMUNE RESPONSE; IMMUNOGENICITY; LACTOCOCCUS LACTIS; PNEUMOCOCCAL INFECTION; RESPIRATORY TRACT INFECTION; REVIEW;

ANIMALIA; BACTERIA (MICROORGANISMS); LACTOCOCCUS LACTIS; STREPTOCOCCUS PNEUMONIAE;

EID: 78449292477     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bbug.1.5.12086     Document Type: Review

References (95)

1. Selwyn BJ. The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Coordinated Data Group of BOSTID Researchers. Rev Infect Dis 1990; 12:870-888.
2. Scott JA. The global epidemiology of childhood pneumonia 20 years on. Bull World Health Organ 2008; 86:494-496.
3. Mulholland K. Childhood pneumonia mortality, a permanent global emergency. Lancet 2007; 370:285-289.
4. Ruvinsky R, Gentile A, Regueira M, Corso A. Infecciones invasivas por Streptococcus pneumoniae: estudio epidemiológico e importancia del desarrollo de un sistema de vigilancia. Arch Argent Pediatr 2002; 100:31-43.
5. Michail SK, Stolfi A, Johnson T, Onady GM. Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2008; 101:508-516.
6. Sanz Y, Nadal I, Sánchez E. Probiotics as drugs against human gastrointestinal infections. Recent Pat Antiinfect Drug Discov 2007; 2:148-156.
7. Lim IS, Lee HS, Kim WY. The effect of lactic acid bacteria isolates on the urinary tract pathogens to infants in vitro. J Korean Med Sci 2009; 24:57-62.
8. Bermúdez-Humarán LG, Langella P, Cortes-Perez NG, Gruss A, Tamez-Guerra RS, Oliveira SC, et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen- specific Th1 cytokine production. Infect Immun 2003; 71:1887-1896.
9. Enouf V, Langella P, Commissaire J, Cohen J, Corthier G. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol 2001; 67:1423-1428.
10. Miyoshi A, Poquet I, Azevedo V, Commissaire J, Bermudez-Humaran L, Domakova E, et al. Controlled production of stable heterologous proteins in Lactococcus lactis. Appl Environ Microbiol 2002; 68:3141-3146.
11. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5:83-93.
12. Vila-Córcoles A. Vaccinate your child and save its grandparents from a heart attack? Current perspectives in anti-pneumococcal vaccination. J Intern Med 21.
13. th ed. Philadelphia: Saunders 2003; 529-588.
14. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; 23:000422
15. Lynch JP, Zhanel GG. Streptococcus pneumoniae: Epidemiology, risk factors and strategies for prevention. Semin Respir Crit Care Med 2009; 30:189-209.
16. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage JAMA 2007; 297:1825-1826.
17. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008; 32:199-206.
18. Katsurahara T, Hotomi M, Yamauchi K, Billal DS, Yamanaka N. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA). J Infect Chemother 2008; 14:393-8.
19. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. Development of a vaccine against invasive pneumococcal disease based on combination of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007; 75:350-357.
20. Cao J, Li D, Gong Y, et al. Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin Exp Immunol 2009; 156:52-60.
21. Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006; 32:139-153.
22. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20:2431 8.
23. Villena J, Racedo S, Agüero G, Bru E, Medina M, Alvarez S. Lactobacillus casei improves resistance to pneumococcal respiratory infection in malnourished mice. J Nutr 2005; 135:1462-1469.
24. Racedo S, Villena J, Medina M, Agüero G, Rodríguez V, Alvarez S. Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection. Microbes Infect 2006; 8:2359-2366.
25. Holt PG, Strickland DH, Wikström ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol 2008; 8:142-152.
26. Lambrecht BN. Alveolar macrophage in the driver's seat. Immunity 2006; 24:366-368.
27. Bergeron Y. and Bergeron MG. Why does pneumococcus kill? Can J Infect Dis 1999; 10:49 60.
28. Lambretch BN, Prins JB, Hoogsteden HC. Lung dendritic cells and host immunity to infection. Eur Respir J 2001; 18:692-704.
29. Dupuis M, McDonald DM. Dendritic-cell regulation of lung immunity. Am J Respir Cell Mol Biol 1997; 17:284-286.
30. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145-173. Review.
31. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236:944-947.
32. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with Inflammatory properties. Semin Immunol 2007; 19:362-371.
33. Corthésy B. Recombinant immunoglobulin A: powerful tools for fundamental and applied research. Trends Biotechnol 2002; 20:65-71.
34. Kiyono H, Fukuyama S. NALT- versus Peyer's-patchmediated mucosal immunity. Nat Rev Immunol 2004; 4:699-710.
35. Twigg HL. Humoral immune defense (antibodies): recent advances. Proc Am Thorac Soc 2005; 2:417-421.
36. Moore BB, Moore TA, Toews GB. Role of T- and B-lymphocytes in pulmonary host defences. Eur Respir J 2001; 18:846-56.
37. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nature Rev Microbiol 2008; 5:349-362.
38. Gilbert C, Robinson K, Le Page RWF, Wells JM. Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect Immun 2000; 68:3251-3260.
39. Nierop Groot Mn, Godefrooij J, Kleerebezem M. Heterologous expression of the pneumococcal serotype 14 polysaccharide in Lactococcus lactis requires lactococcal epsABC regulatory genes. Appl Environ Microbiol 2008; 74:912-915.
40. Mierau I and Kleerebezem M. 10 years of the nisincontrolled gene expression system (NICE). Appl Microbiol Biotechnol 2005; 68:705-717.
41. Boesma T, Kanninga R, Neef J, Audouy SAL, van Roosmalen ML, Steen A, et al. Novel surface display system for proteins on non-genetically modified Gram-positive bacteria. Appl Environ Microbiol 2006; 72:880-889.
42. van Roosmalen ML, Kanninga R, El Khattabi M, Neef J, Audouy S, Bosma T, et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 2006; 38:144-149.
43. st ed. London: Kluwer Academic Publishers 2000; 234 70.
44. Kiyono H, Fukuyama S. NALT-versus Peyer's patch mediated mucosal immunity. Nature Rev Immunol 2004; 4:699-710.
45. Hussell T, Humphreys IR. Nasal vaccination induces protective immunity without mmunopathology. Clin Exp Immunol 2002; 130:359-362.
46. Cangemi de Gutierrez R, Santos V, Nader-Macías ME. Protective effect of intranasally inoculated Lactobacillus fermentum against Streptococcus pneumoniae challenge on the mouse respiratory tract. FEMS Immunol Med Microbiol 2001; 31:187-195.
47. Mercenier A, Muller-Alouf H, Grangette C. Lactic acid bacteria as live vaccines. Curr Issues Mol Biol 2000; 2:17-25.
48. Mannam P, Jones KF, Geller BL. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun 2004; 72:3444-3450.
49. Medina M, Villena J, Salva S, Vintiñi E, Langella P, Alvarez S. Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Microbiol Immunol 2008; 52:399-409.
50. Fowler NG. Antimicrobials and competitive exclusion. Int J Food Microbiol 1992; 15:277-279.
51. Standford TJ, Kunkel SL, Greenberger MJ, Laichalk LL, Strieter RM. Expression and regulation of chemokines in bacterial pneumonia. J Leukoc Biol 1996; 59:24-28.
52. Nelson S, Summer WR. Innate immunity, cytokines and pulmonary host defense. Infect Dis Clin North Am 1998; 12:555-567.
53. Furfaro S, Berman JS, Center DM. Determinants of T cell migration in the lung. In: Kradin RL, Robinson BWS, eds. Immunopathology of Lung Disease, Boston: NJ: Butterworth Heinemann 1996; 15-32.
54. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedruf JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992; 89:6901-6905.
55. Brandtzaeg P. Humoral immune response patterns of human mucosae: induction and relation to bacterial respiratory tract infections. J Infect Dis 1992; 165:167-176.
56. Janoff EN, Fasching C, Oresnstein JM, Rubins JB, Osptad NL, Dalmasso AP. Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement and phagocytes. J Clin Invest 1999;104:1139-1147.
57. Favre L, Spertini F, Corthesy B. Secretory IgA possess intrinsic modulatory properties stimulating mucosal and systemic immune responses. J Immunol 2005; 175:2793-2800.
58. García VE, Gherardi MM, Iglesias MF, Cerquetti MC, Sordelli DO. Local and systemic immunity against Streptococcus pneumoniae: Humoral responses against a non-capsulated temperature-sensitive mutant. FEMS Microbiol Lett 1993; 108:163-167.
59. Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor alpha, interleukin-6 and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996; 64:5403-5405.
60. Blum S, Delneste Y, Alvarez S, Haller D, Pérez PF, Bode C, et al. Interactions between commensal bacteria and mucosal immunocompetent cells. Internat Dairy J 1999; 9:63-68.
61. Yam KK, Pouliot P, N'diaye MM, Fournier S, Olivier M, Cousineau B. Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis. Vaccine 2008; 26:2689-2699.
62. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J ExpMed 2005; 201:1771-1780.
63. Audouy SAL, van Roosmalen ML, Neef J, Kanninga R, Post R, van Deemter M, et al. Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine 2006; 24:5434-5441.
64. Tamura S, Ito Y, Asmuma H, Hirabayashi Y, Suzuki Y, Nagamine T, et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immun 1992; 149:981-982.
65. Wilschut J, de Haan A, Geerligs HJ, Huchshorn JP, van Scharrenburg GJM, Palache AM, et al. Liposomes as a mucosal adjuvant system: an intranasal liposomal influenza subunit vaccine and the role of IgA in nasal antiinfluenza immunity. J Liposome Res 1994; 4:301-314.
66. Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW. Pneumococcal surface adhesin A (PsaA): a review. Crit Rev Microbiol 2008; 34:131-142.
67. Oliveira MLS, Areas APM, Campos IB, Monedero V, Perez-Martínez G, Miyaji EN, et al. Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infect 2006; 8:1016-1024.
68. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ. Peumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae 1999; 67:4720-4724.
69. Hanniffy SB, Carter AT, Hitchin E, Wells JM. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Disease 2007; 195:185-193.
70. Cao J, Gong Y, Li D, Yin N, Chen T, Xu W, et al. CD4(+) T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA. Vaccine 2009; 27:2838-2844.
71. Medina M, Villena J, Vintiñi E, Hebert EM, Raya R, Alvarez S. Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect Immun 2008; 76:2696-2705.
72. Mawas F, Feavers IM, Corbel MJ. Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1:Th2 cytokine profile and IgG subclass response to pneumococcal-CRM197 conjugate vaccines in a murine model. Vaccine 2001; 19:1159-1166.
73. Vintiñi E, Villena J, Alvarez S, Medina M. Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin Exp Immunol 2010; 159:351-362.
74. Audouy SAL, van Selm S, van Roosmalen ML, Post E, Kanninga R, Neef J, et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 2007; 25:2497-2506.
75. Perdigon G, Fuller R, Raya R. Lactic acid bacteria and their effect on the immune system. Curr Issues Intest Microbiol 2001; 2:27-42.
76. Torres Vitela MR. In: Flora intestinal, probióticos y salud. Formas finas, eds. Guadalajara, México 2002; 119-32.
77. Alvarez S, Villena J, Racedo S, Salva S, Agüero G. Malnutrition, probiotics and respiratory infections. In: Research Advances in Nutrition. Global Research Network, ed. India 2007; 9-23.
78. Cross M. Microbes versus microbes: immune signals generated by probiotic lactobacilli and their role in protection against microbial pathogens. FEMS Immunol Med Microbiol 2002; 34:245-253.
79. Racedo S, Villena J, Medina M, Agüero G, Rodríguez V, Alvarez S. Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection Microbes Infect 2006; 8:2359-66.
80. Alvarez S, Herrero C, Bru E, Perdigón G. Effect of Lactobacillus casei and yogurt administration on prevention of Pseudomona aeuriginosa infection in young mice. J Food Prot 2001; 64:1768-1774.
81. Villena J, Racedo S, Aguero G, Bru E, Medina M, Alvarez S. Lactobacillus casei improves resistance to pneumococcal respiratory infection in malnourished mice J Nutr 2005; 135:1462-9.
82. Villena J, Racedo S, Aguero G, Alvarez S. Yogurt accelerates the recovery of defence mechanisms against Streptococcus pneumoniae in protein malnourished mice Br J Nutr 2006; 95:591-602.
83. Salva S, Villena J, Racedo S, Alvarez S, Agüero G. Lactobacillus casei addition to a repletion diet induced early normalization of cytokine profiles during pneumococcal infection in malnourished mice. Food Agricult Immunol 2008; 19:195-211
84. Villena J, Medina M, Vintiñi E, Alvarez S. Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Can J Microbiol 2008; 54:630-8.
85. Salva S, Villena J, Alvarez S. Differential immunomodulatory activity of Lactobacillus rhamnosus strains isolated from goat milk: impact on intestinal and respiratory infections. Int J Food Microbiol 2009; In press.
86. Le Loir Y, Azevedo V, Oliveira SC, Freitas DA, Miyoshi A, Bermúdez-Humarán LG, et al. Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microb Cell Fact 2005; 4:2-9.
87. Galdeano CM, de Moreno de LeBlanc A, Vinderola G, Bonet ME, Perdigón G. Proposed model: mechanisms of immunomodulation induced by probiotic bacteria. Clin Vaccine Immunol 2007; 14:485-492.
88. Perdigon G, Alvarez S, Medina M, Vintiñi E, Roux E. Influence of the oral administration of lactic acid bacteria on IgA producing cells associated to bronchus. Int J Immunopathol Pharmacol 1999; 12:97-102.
89. Perdigon G, Vintiñi E, Alvarez S, Medina M, Medici M. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. J Dairy Sci 1999; 82:1108-14.
90. Villena J, Medina M, Raya R, Alvarez S. Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection. Can J Microbiol 2008; 54:845-853.
91. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use. Clin Infect Dis 2000; 30:122-140.
92. Villena J, Medina M, Racedo S, Alvarez S. Resistance of young mice to pneumococcal infection can be improved by oral vaccination with recombinant Lactococcus lactis. J Microbiol Immunol Infect 2010; 43:1-10.
93. Yam KK, Pouliot P, N'diaye MM, Fournier S, Olivier M, Cousineau B. Innate inflammatory responses to the Gram-positive bacterium Lactococcus lactis. Vaccine 2008; 26:2689-2699.
94. Kiyono H, Fukuyama S. NALT-versus Peyer's patch mediated mucosal immunity. Nat Rev Immunol 2004; 4:699-710.
95. Campos IB, Darrieux M, Ferreira DM, Miyaji EN, Silva DA, Áreas PAM, et al. Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes Infect 2008; 10:481-488.